The goal of this research is to develop two fluorescence in situ hybridization (FISH) assays for detecting the t(8;21)(q22;q22) and inv(16)(p13q22) and related t(16;16)(p13;q22) translocations found in two different subsets of acute myeloid leukemia (AML), M2 and M4Eo, respectively. These cancers are traditionally treated by chemotherapy; however, many patients relapse and become refractory to treatment. Diagnosis and post treatment follow-up are currently performed by karyotype, Southern blotting or PCR. These methods, however, have limitations in specificity and/or sensitivity. A precise, reliable and simple method for detecting cancer cells, especially in post-treatment specimens, is needed. FISH is an improvement over current methods used for detecting translocations; however, no clinically tested probes are available for detecting AML. This SBIR proposal aims to develop novel, sensitive and specific FISH assays that will unambiguously detect translocation carrying nuclei in diagnostic and follow up patient samples.

Proposed Commercial Applications

The proposed research will provide highly specific and sensitive FISH assays for detecting chromosomal translocations present in Acute Myeloid Leukemia (AML) for use in cancer cytogenetic reference laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA091532-01
Application #
6338187
Study Section
Special Emphasis Panel (ZRG1-SSS-Y (10))
Program Officer
Couch, Jennifer A
Project Start
2001-08-01
Project End
2002-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$226,508
Indirect Cost
Name
Cancer Genetics, Inc.
Department
Type
DUNS #
015091395
City
Rutherford
State
NJ
Country
United States
Zip Code
07070
Palanisamy, Nallasivam (2010) Chromosomal translocations in AML: detection and prognostic significance. Cancer Treat Res 145:41-58